Healio (3/18, Ellis) reported, “Compared with other first-line osteoporosis treatments, alendronate therapy yielded an increased risk for depression and anxiety,” researchers concluded in a study that “analyzed more than 100,000 adverse events reports from the FDA Adverse Event Reporting System…and the WHO’s VigiAccess adverse drug reactions global database.” The findings were published online in the journal Scientific Reports. (SOURCE: APA Headlines)